Cipla Ltd. (CIPLA) fundamentals
Cipla Ltd. is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as CIPLA (ISIN INE059A01026). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Cipla Ltd. does
Cipla Limited is an India-based global pharmaceutical company. The Company is engaged in manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The Company operates through two segments: Pharmaceuticals and New ventures. The Pharmaceuticals segment is engaged in developing, manufacturing, selling, and distributing generic or branded generic medicines, as well as Active Pharmaceutical Ingredients (API). The New ventures segment includes the operations of the Company, a consumer healthcare, Biosimilars and specialty business. Its product portfolio spans complex generics, as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective and central nervous system (CNS). Its geographical segments include India, the United States, South Africa, and the Rest of the World. It has its network of manufacturing, trading and other incidental operations in India and International markets.
Valuation and market data
| Last close | ₹1355.00 |
|---|---|
| Market capitalisation | ₹1.09 lakh crore |
| Enterprise value | ₹1.09 lakh crore |
| P/E (TTM) | 28.21 |
| Price to book | 3.16 |
| Price to sales (TTM) | 2.16 |
| Book value per share | ₹428.45 |
| Dividend yield | 95.94% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Wed Feb 08 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹20,103 crore | ₹4,636 crore | ₹3,515 crore | 43.52 |
| Mar 2025 | ₹20,030 crore | ₹6,469 crore | ₹5,158 crore | 63.87 |
| Mar 2024 | ₹17,645 crore | ₹4,947 crore | ₹3,714 crore | 50.51 |
| Mar 2023 | ₹14,802 crore | ₹3,006 crore | ₹2,144 crore | 31.15 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 29.2% |
|---|---|
| Foreign institutions (FII) | 20.2% |
| Mutual funds | 20.6% |
| Other domestic institutions | 14.1% |
| Retail and others | 15.9% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.